Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07162363 · ClinicalTrials.gov registry record · Phase 2
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT07162363 is a Phase 2 study that has not yet begun recruiting, run by University of Illinois at Chicago. The registered enrollment target is 240 participants.
The verdict
NCT07162363, a Phase 2 study, has not yet begun recruiting, sponsored by University of Illinois at Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.
Interventions
- DRUG Deferoxamine
- PROCEDURE Minimally Invasive surgery (MIS)
- OTHER Standard Medical Care (SMD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07162363
The ClinicalTrials.gov registry entry for NCT07162363 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Deferoxamine is the first listed.
NCT07162363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07162363 about?
NCT07162363 is a clinical study titled "Synergistic Minimally Invasive Surgery and Deferoxamine in ICH". This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This t...
What is the current status of trial NCT07162363?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-03-01. Estimated completion is 2028-12-30.
What interventions are being tested in trial NCT07162363?
The interventions under investigation include: Deferoxamine (DRUG), Minimally Invasive surgery (MIS) (PROCEDURE), Standard Medical Care (SMD) (OTHER).
Who is sponsoring clinical trial NCT07162363?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.